Nabi Biopharmaceuticals Announces Third Quarter 2007 Financial Results and Positive Vote from November 8, 2007 Special Stockholde...(92) 212 (9274) Net loss...),Health

Net loss $ (15,874) $(21,813) $(31,681) $(54,714)

Basic and diluted

(loss) income per

share:

Continuing

operations $(0.26) $(0.27) $(0.52) $(0.75)

Discontinued

operations 0.00 (0.09) 0.00 (0.15)

Basic and diluted

loss per share $(0.26) $(0.36) $(0.52) $(0.90)

Basic and diluted

weighted average

shares outstanding 61,382 61,185 61,256 60,830

Nabi Biopharmaceuticals

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(in thousands)

For the Nine Months Ended

September 29, September 30,

2007 2006

Cash flow from operating activities:

Loss from continuing operations $(31,893) $(45,440)

Adjustments to reconcile loss from

continuing operations to net cash used

in operating activities from continuing

operations:

Depreciation and amortization 6,115 5,593

Provision for slow moving or obsolete

inventory 239 1,082

Non-cash compensation 2,478 5,007

Gain on sale of assets, net (2,557) -

Loss on disposal of fixed assets, net 44 452

Tax benefit on stock options exercised - (162)

Other 149 (328)

Changes in assets and liabilities:

Trade accounts receiv
'/>"/>